199 related articles for article (PubMed ID: 8960716)
1. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
[TBL] [Abstract][Full Text] [Related]
2. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
van Dyck CH; Newhouse P; Falk WE; Mattes JA
Arch Gen Psychiatry; 2000 Feb; 57(2):157-64. PubMed ID: 10665618
[TBL] [Abstract][Full Text] [Related]
3. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
Thal LJ; Ferguson JM; Mintzer J; Raskin A; Targum SD
Neurology; 1999 Apr; 52(6):1146-52. PubMed ID: 10214735
[TBL] [Abstract][Full Text] [Related]
4. Physostigmine for Alzheimer's disease.
Coelho F; Birks J
Cochrane Database Syst Rev; 2001; 2001(2):CD001499. PubMed ID: 11405996
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Imbimbo BP; Martelli P; Troetel WM; Lucchelli F; Lucca U; Thal LJ
Neurology; 1999 Mar; 52(4):700-8. PubMed ID: 10078713
[TBL] [Abstract][Full Text] [Related]
6. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease.
Imbimbo BP; Troetel WM; Martelli P; Lucchelli F
Dement Geriatr Cogn Disord; 2000; 11(1):17-24. PubMed ID: 10629357
[TBL] [Abstract][Full Text] [Related]
7. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
8. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
Imbimbo BP; Lucca U; Lucchelli F; Alberoni M; Thal LJ
Alzheimer Dis Assoc Disord; 1998 Dec; 12(4):313-22. PubMed ID: 9876959
[TBL] [Abstract][Full Text] [Related]
9. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group.
Le Bars PL; Katz MM; Berman N; Itil TM; Freedman AM; Schatzberg AF
JAMA; 1997 Oct 22-29; 278(16):1327-32. PubMed ID: 9343463
[TBL] [Abstract][Full Text] [Related]
12. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.
Xiao S; Wang T; Ma X; Qin Y; Li X; Zhao Z; Liu X; Wang X; Xie H; Jiang Q; Sun L; Luo B; Shang L; Chen W; Bai Y; Tang M; He M; Wu L; Ma Q; Hou D; He J
Age Ageing; 2017 Sep; 46(5):767-773. PubMed ID: 28419192
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
17. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.
Imbimbo BP; Verdelli G; Martelli P; Marchesini D
Dement Geriatr Cogn Disord; 1999; 10(2):139-47. PubMed ID: 10026388
[TBL] [Abstract][Full Text] [Related]
18. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group.
Farlow M; Gracon SI; Hershey LA; Lewis KW; Sadowsky CH; Dolan-Ureno J
JAMA; 1992 Nov; 268(18):2523-9. PubMed ID: 1404819
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
Möller H-J ; Hampel H; Hegerl U; Schmitt W; Walter K
Pharmacopsychiatry; 1999 May; 32(3):99-106. PubMed ID: 10463377
[TBL] [Abstract][Full Text] [Related]
20. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL; Farlow MR; Doody RS; Mohs R; Friedhoff LT
Neurology; 1998 Jan; 50(1):136-45. PubMed ID: 9443470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
